A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
PhRMA, a leading drug industry trade group, and the US Chamber of Commerce have also filed suits. More on Medicare drug pricing: Medicare lists first ten drugs selected for pricing negotiations ...
The nation’s leading lobbying group for seniors filed an amicus brief on Monday in Washington, D.C., urging a federal court ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
Boehringer Ingelheim is the latest large drugmaker to challenge the U.S. government over Medicare’s new power to negotiate prices of select top-selling medicines, filing a 62-page lawsuit Friday ...
While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations ...
AARP announced Thursday it would join the US government in two additional lawsuits brought by drug companies suing over Medicare drug pricing negotiations, which are set to begin next month.
A group of Republicans has called the Biden administration's list of the first 10 drugs that will face Medicare price negotiations a form of price controls that will end up leading to fewer new ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
AARP announced Thursday it would join the US government in two additional lawsuits brought by drug companies suing over Medicare drug pricing negotiations, which are set to begin next month.
